argenx SE (ARGX) Stock Price & Analysis
argenx SE (ARGX) closed at USD 875.76 on Thursday, October 22, 2026, down 1.61% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 890.05; the Oct 22, 2026 session ranged USD 853.28–897.27 on volume of 1,006,127 shares. Market capitalization is $55.07B, with a 52-week range of USD 661.85–1,072.75 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:08 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ARGX.md
Key facts (ARGX)
- Analysts: Buy (mean 1.84 on a 1–5 scale) (25 analysts), mean target USD 1,150.91 (range 861–1,356).
- Total return with dividends: 1Y +7.8% vs S&P 500 +14.9%; 5Y +198.7% vs S&P 500 +80.3%.
- Next earnings: 2026-10-22, EPS estimate USD 7.32, revenue estimate $1.89B.
Analysts (ARGX)
Consensus Buy (mean 1.84 on a 1–5 scale), 25 analysts; mean target USD 1,150.91 (low 861, high 1,356).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-20 | RBC Capital | Target lowered | Outperform | $1100 → $1025 |
| 2026-10-14 | Wells Fargo | Target raised | Overweight | $1355 → $1356 |
| 2026-10-12 | Oppenheimer | Target lowered | Outperform | $1100 → $1038 |
| 2026-10-09 | Evercore ISI Group | Target lowered | Outperform | $1175 → $1078 |
| 2026-10-09 | Baird | Target lowered | Neutral | $932 → $823 |
| 2026-09-08 | Wedbush | Reiterated | Outperform | $1150 |
| 2026-09-03 | Wedbush | Reiterated | Outperform | $1150 |
| 2026-08-31 | Morgan Stanley | Target raised | Overweight | $1230 → $1250 |
| 2026-08-26 | UBS | Upgrade | Neutral → Buy | $960 → $1400 |
| 2026-08-26 | Wells Fargo | Target raised | Overweight | $1350 → $1415 |
| 2026-08-18 | Truist Securities | Target raised | Buy | $1030 → $1095 |
| 2026-08-18 | Morgan Stanley | Target raised | Overweight | $1200 → $1230 |
Total return (dividends reinvested) (ARGX)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +7.8% | +198.7% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +7.9% | +24.4% |
| Volatility (annualized) | 36.9% | 37.9% |
| Max drawdown | -28.6% (Nov 2025→Mar 2026) | -34.3% (Jul 2023→Apr 2024) |
ARGX suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | AbbVie (ABBV) | “currently have collaborative research relationships with various pharmaceutical companies such as AbbVie, Zai Lab and” |
| Partner | HALOZYME THERAPEUTICS, INC. (HALO) | “In February 2019, the Company entered into a global collaboration and license agreement with Halozyme Therapeutics,” |
| Partner | Lonza | “The Company's commercial supply is manufactured in collaboration with Lonza and Fujifilm.” |
Quoted from the company's 20-F filed Mar 19, 2026.
ARGX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $7.32 | $8.14 | -10.1% | $1.89B | 2 |
| Next quarter (ends Mar 2027) | $6.49 | $7.93 | -18.2% | $1.85B | 1 |
| Current fiscal year (ends Dec 2026) | $28.27 | $27.83 | +1.6% | $6.37B | 4 |
| Next fiscal year (ends Dec 2027) | $33.31 | $39.05 | -14.7% | $7.77B | 4 |
ARGX options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 34.6% | ±7.8% |
| Dec 18, 2026 | 56 | 39.0% | ±12.3% |
| Jan 15, 2027 | 84 | 39.1% | ±15.0% |
| Feb 19, 2027 | 119 | 38.6% | ±17.6% |
| Mar 19, 2027 | 147 | 38.9% | ±19.7% |
| May 21, 2027 | 210 | 39.4% | ±23.9% |
30-day implied volatility 36.2% vs 46.8% realized over the last 30 trading days. Put/call ratio (volume) 1.86. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 10:08 UTC)
| Price | USD 875.76 |
|---|---|
| Change | ▼ 1.61% (down) |
| Previous Close | USD 890.05 |
| Open | USD 853.28 |
| Day Range | USD 853.28 – 897.27 |
| 52-Week Range | USD 661.85 – 1,072.75 |
| Volume | 1,006,127 shares |
| Market Cap | $55.07B |
| Exchange | NMS |
Technical Analysis (ARGX)
Nexqual's technical model rates ARGX "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:08 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 43.7 (neutral) |
| vs SMA50 | Below (USD 952.65) |
| MACD | -28.41 (negative) |
Analyst Ratings (ARGX)
Wall Street analysts rate ARGX "Buy" based on 25 analysts, with a mean price target of USD 1,150.91 (range USD 861–1,356), per Nexqual as of October 23, 2026 at 10:08 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 25 |
| Mean Target | USD 1,150.91 |
| High Target | USD 1,356 |
| Low Target | USD 861 |
| Buy / Hold / Sell | 22 / 3 / 0 |
Earnings (ARGX)
| Next Earnings Date | 2026-10-22 |
|---|---|
| EPS Estimate | USD 7.32 |
| Revenue Estimate | $1.89B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD 7.8 vs est -27.83 ▲ beat |
| 2026-06-30 | USD 7.32 vs est 6.19 ▲ beat |
| 2026-03-31 | USD 5.52 vs est 4.92 ▲ beat |
| 2025-12-31 | USD 8.02 vs est 6.11 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:08 UTC.
Financials & Fundamentals (ARGX)
| Total Revenue | $5.32B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +59.30% |
| Gross Margin | +59.07% |
| Operating Margin | +31.99% |
| Profit Margin | +32.27% |
| ROE | +23.64% |
| Debt / Equity | 0.01 |
| Current Ratio | 5.12 |
| Total Cash | $5.18B |
| Total Debt | $47.00M |
Source: Nexqual, October 23, 2026 at 10:08 UTC.
Financial Health Score (ARGX)
Nexqual rates argenx SE's overall financial health "Strong" across five dimensions, as of October 23, 2026 at 10:08 UTC.
| Growth | Strong — Revenue +89% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 59%, operating 32% (last 12 months) |
| Balance Sheet | Strong — $5.18B cash vs $47M debt, net cash position |
| Cash Flow | Solid — Operating cash flow $974M (TTM) |
| Efficiency | Strong — ROE 24%, ROA 11.6% |
Ownership (ARGX)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +46.12% |
| Shares Outstanding | 62.89M |
| Float | 1.56B |
| Short % of Float | +2.16% |
Source: Nexqual, October 23, 2026 at 10:08 UTC.
Leadership (ARGX)
argenx SE is led by Karen Massey, CEO & Executive Director, per Nexqual as of October 23, 2026 at 10:08 UTC.
| CEO & Executive Director | Karen Massey |
|---|---|
| Co-Founder & Non-Independent Non-Executive Chairman of the Board | Timothy Van Hauwermeiren EMBA, M.Sc. |
| Chief Financial Officer | Karl Gubitz |
| Chief Scientific Officer | Peter Ulrichts |
| Chief Technology Innovation Officer | Filip Borgions |
Major Backers & Investors (ARGX)
Notable institutional backers of argenx SE include FMR, LLC, Price (T.Rowe) Associates Inc, Jupiter Topco LLC, according to Nexqual as of October 23, 2026 at 10:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 8.32% |
| Price (T.Rowe) Associates Inc | 4.26% |
| Jupiter Topco LLC | 3.93% |
| Capital Group | 3.5% |
| Artisan Partners Limited Partnership | 2.4% |
| Fidelity | 2.1% |
| Avoro Capital Advisors LLC | 1.59% |
| AMERICAN FUNDS INSURANCE SERIES-Eupac Fund | 1.51% |
Source: Nexqual, October 23, 2026 at 10:08 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ONC | BeOne Medicines Ltd. | USD 382.27 | ▼ 1.08% |
| MRNA | Moderna, Inc. | USD 202.63 | ▼ 17.57% |
| RVMD | Revolution Medicines, Inc. | USD 187.69 | ▼ 3.39% |
| REGN | Regeneron Pharmaceuticals, Inc. | USD 819.09 | ▲ 1.67% |
| RPRX | Royalty Pharma plc | USD 63.75 | ▲ 2.57% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 227.28 | ▲ 0.97% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:08 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt